TUESDAY, SEPTEMBER 22

Cancer (3pm Denver/Mountain Time Start)

Ontogeny of Myeloid Cells in Cancer (8:30am Denver/Mountain Time Start)

Opening Remarks and Keynote Address (8am Denver/Mountain Time Start)

MONDAY, SEPTEMBER 21

For the most up-to-date details, visit https://www.keystonesymposia.org.

* Session Chair † Invited but not yet accepted

Sci...
Ziyan Zoe Xu, The Salk Institute, USA  
Short Talk: Lipid Metabolism Controls Macrophage Functional Reprogramming in Tumor Microenvironment

**WEDNESDAY, SEPTEMBER 23**

**Targeting Myeloid Cells in Cancer Therapy I (8am Denver/Mountain Time Start)**

*Lisa M. Coussens*, Oregon Health & Science University, USA  
Therapeutic Targeting of Macrophages: Lessons Learned from Mouse Models and Their Translation to the Clinic

*Limin Shang*, Light Chain Bioscience, Switzerland  
CD47 Targeting in Cancer Therapy

*Simon T. Barry*, AstraZeneca, UK  
Therapeutic Targeting of Macrophages and Neutrophils

*Nagy A. Habib*, Imperial College London and MiNA Therapeutics, UK  
MTL - CEBPA - Next Generation Immunotherapy Targeting Myeloid Cell Differentiation

*Sven Brandau*, University Hospital Essen, Germany  
Short Talk: Unravelling the Identity and Function of MDSC in Human Cancer Patients

*Yolanda Calle*, University of Roehampton, UK  
Short Talk: Therapeutic Drugs Promote Differentiation of AML Blasts to a Mixed M1/M2 and Migratory Phenotype Resistant to Treatment Facilitated by the Bone Marrow Microenvironment.

*Natalie Horvat*, European Molecular Biological Laboratories, Germany  
Short Talk: Polarization of TAMs by Iron Nanoparticles as an Adjuvant Lung Cancer Therapy

**Poster Session (1:30pm Denver/Mountain Time Start)**

**Targeting Myeloid Cells in Cancer Therapy II (3pm Denver/Mountain Time Start)**

*Brenda C. O’Connell*, Infinity Pharmaceuticals, Inc, USA  
Targeting PI3K-gamma with IPI-549, a Tumor Macrophage-Reprogramming Small Molecule, in Patients with Advanced Solid Tumors

*Jennifer Guerriero*, Dana-Farber Cancer Institute, USA  
Differentiating Macrophages are Regulated by PARP Inhibitors and can be Harnessed to Overcome PARP-Inhibitor Resistance in BRCA-Associated Triple-Negative Breast Cancer

*David A. Cheresh*, University of California, San Diego, USA  
Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression

*Caroline Bonnans*, Immune-Onc Therapeutics, USA  
Short Talk: Antagonistic Antibodies Targeting LAIR1 Promote Inflammatory Phenotypes in Myeloid Cells and Activate Lymphocytes

*Shadi Swaidani*, Cleveland Clinic Foundation, USA  
Short Talk: Elevated Systemic Myeloid-Derived Suppressor Cells and Interleukin 8 Correlate with Increased Incidence of Venous Thromboembolism in Cancer Patients Receiving Immune-Checkpoint Inhibitors

*Mehdi Chaib*, University of Tennessee Health Science Center, USA  
Short Talk: PKC Delta Activation Restricts Innate Immune Suppression and Promotes antigen Presentation in Triple Negative Breast Cancer

*Jihong Bae*, Korea Advanced Institute of Science and Technology, South Korea  
Short Talk: Extracellular Vesicles Derived from a Commensal Bacteria Enhance Anticancer Immunity by Modulating Tumor Infiltrating Immune Cells

**Closing Remarks (Organizers) (5:45pm Denver/Mountain Time Start)**